nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—kidney cancer—pancreatic cancer	0.311	1	CtDrD
Sunitinib—STK11—pancreatic cancer	0.165	0.735	CbGaD
Sunitinib—KDR—pancreatic cancer	0.0593	0.265	CbGaD
Sunitinib—ULK3—Erlotinib—pancreatic cancer	0.0371	0.138	CbGbCtD
Sunitinib—TNK1—Erlotinib—pancreatic cancer	0.0371	0.138	CbGbCtD
Sunitinib—AURKC—Erlotinib—pancreatic cancer	0.0295	0.11	CbGbCtD
Sunitinib—SLK—Erlotinib—pancreatic cancer	0.0247	0.0918	CbGbCtD
Sunitinib—FLT3—Erlotinib—pancreatic cancer	0.0213	0.0793	CbGbCtD
Sunitinib—HIPK4—Erlotinib—pancreatic cancer	0.0188	0.0701	CbGbCtD
Sunitinib—STK10—Erlotinib—pancreatic cancer	0.0169	0.063	CbGbCtD
Sunitinib—MAP2K5—Erlotinib—pancreatic cancer	0.0154	0.0573	CbGbCtD
Sunitinib—MAP3K19—Erlotinib—pancreatic cancer	0.0142	0.0527	CbGbCtD
Sunitinib—ABCC4—Fluorouracil—pancreatic cancer	0.00451	0.0168	CbGbCtD
Sunitinib—ABCC2—Tamoxifen—pancreatic cancer	0.00364	0.0135	CbGbCtD
Sunitinib—ABCG2—Tamoxifen—pancreatic cancer	0.00329	0.0122	CbGbCtD
Sunitinib—ABCG2—Erlotinib—pancreatic cancer	0.0028	0.0104	CbGbCtD
Sunitinib—ABCC2—Irinotecan—pancreatic cancer	0.00279	0.0104	CbGbCtD
Sunitinib—ABCG2—Irinotecan—pancreatic cancer	0.00253	0.0094	CbGbCtD
Sunitinib—RET—enteric nervous system—pancreatic cancer	0.00245	0.0612	CbGeAlD
Sunitinib—CYP3A7—Tamoxifen—pancreatic cancer	0.00243	0.00904	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.00243	0.00904	CbGbCtD
Sunitinib—ABCG2—Fluorouracil—pancreatic cancer	0.00242	0.00902	CbGbCtD
Sunitinib—ABCC2—Docetaxel—pancreatic cancer	0.00205	0.00762	CbGbCtD
Sunitinib—CYP3A7—Irinotecan—pancreatic cancer	0.00187	0.00694	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.00187	0.00694	CbGbCtD
Sunitinib—ABCG2—Docetaxel—pancreatic cancer	0.00185	0.00689	CbGbCtD
Sunitinib—CYP3A5—Tamoxifen—pancreatic cancer	0.00182	0.00678	CbGbCtD
Sunitinib—CYP3A5—Erlotinib—pancreatic cancer	0.00155	0.00576	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—pancreatic cancer	0.00153	0.00568	CbGbCtD
Sunitinib—CYP3A5—Irinotecan—pancreatic cancer	0.0014	0.00521	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—pancreatic cancer	0.00138	0.00513	CbGbCtD
Sunitinib—MYLK—umbilical vein—pancreatic cancer	0.00137	0.0343	CbGeAlD
Sunitinib—CYP3A7—Docetaxel—pancreatic cancer	0.00137	0.00509	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00137	0.00509	CbGbCtD
Sunitinib—ABCB1—Tamoxifen—pancreatic cancer	0.00119	0.00441	CbGbCtD
Sunitinib—CYP3A5—Docetaxel—pancreatic cancer	0.00103	0.00382	CbGbCtD
Sunitinib—ABCB1—Gemcitabine—pancreatic cancer	0.00102	0.0038	CbGbCtD
Sunitinib—ABCB1—Erlotinib—pancreatic cancer	0.00101	0.00375	CbGbCtD
Sunitinib—ABCB1—Irinotecan—pancreatic cancer	0.000911	0.00339	CbGbCtD
Sunitinib—ABCC2—bile duct—pancreatic cancer	0.000832	0.0208	CbGeAlD
Sunitinib—FLT1—umbilical vein—pancreatic cancer	0.000765	0.0191	CbGeAlD
Sunitinib—CYP3A4—Tamoxifen—pancreatic cancer	0.000711	0.00264	CbGbCtD
Sunitinib—ABCB1—Docetaxel—pancreatic cancer	0.000667	0.00248	CbGbCtD
Sunitinib—KDR—umbilical vein—pancreatic cancer	0.000647	0.0162	CbGeAlD
Sunitinib—ABCC2—bile—pancreatic cancer	0.00064	0.016	CbGeAlD
Sunitinib—CYP3A4—Erlotinib—pancreatic cancer	0.000604	0.00225	CbGbCtD
Sunitinib—MYLK—gall bladder—pancreatic cancer	0.000565	0.0141	CbGeAlD
Sunitinib—CYP3A4—Irinotecan—pancreatic cancer	0.000546	0.00203	CbGbCtD
Sunitinib—LATS2—islet of Langerhans—pancreatic cancer	0.000505	0.0126	CbGeAlD
Sunitinib—PAK3—islet of Langerhans—pancreatic cancer	0.000505	0.0126	CbGeAlD
Sunitinib—ABCB1—Doxorubicin—pancreatic cancer	0.000498	0.00185	CbGbCtD
Sunitinib—DAPK1—islet of Langerhans—pancreatic cancer	0.000463	0.0116	CbGeAlD
Sunitinib—BRD4—islet of Langerhans—pancreatic cancer	0.000449	0.0112	CbGeAlD
Sunitinib—RPS6KA1—islet of Langerhans—pancreatic cancer	0.000444	0.0111	CbGeAlD
Sunitinib—ERN1—pancreas—pancreatic cancer	0.000412	0.0103	CbGeAlD
Sunitinib—OXSR1—islet of Langerhans—pancreatic cancer	0.00041	0.0102	CbGeAlD
Sunitinib—INSR—islet of Langerhans—pancreatic cancer	0.00041	0.0102	CbGeAlD
Sunitinib—STK38—islet of Langerhans—pancreatic cancer	0.000403	0.0101	CbGeAlD
Sunitinib—RPS6KA2—islet of Langerhans—pancreatic cancer	0.000403	0.0101	CbGeAlD
Sunitinib—CYP3A4—Docetaxel—pancreatic cancer	0.0004	0.00149	CbGbCtD
Sunitinib—PKN1—islet of Langerhans—pancreatic cancer	0.000397	0.00991	CbGeAlD
Sunitinib—CSNK1G2—islet of Langerhans—pancreatic cancer	0.000397	0.00991	CbGeAlD
Sunitinib—PRPF4—islet of Langerhans—pancreatic cancer	0.000391	0.00976	CbGeAlD
Sunitinib—PRPF4B—islet of Langerhans—pancreatic cancer	0.000386	0.00963	CbGeAlD
Sunitinib—STK39—islet of Langerhans—pancreatic cancer	0.00038	0.00949	CbGeAlD
Sunitinib—CSNK2A1—islet of Langerhans—pancreatic cancer	0.000375	0.00937	CbGeAlD
Sunitinib—MYLK—islet of Langerhans—pancreatic cancer	0.00037	0.00925	CbGeAlD
Sunitinib—LATS2—pancreas—pancreatic cancer	0.000355	0.00887	CbGeAlD
Sunitinib—PAK3—pancreas—pancreatic cancer	0.000355	0.00887	CbGeAlD
Sunitinib—ERN1—digestive system—pancreatic cancer	0.000352	0.00879	CbGeAlD
Sunitinib—PIP4K2B—digestive system—pancreatic cancer	0.000352	0.00879	CbGeAlD
Sunitinib—STK16—islet of Langerhans—pancreatic cancer	0.000346	0.00862	CbGeAlD
Sunitinib—HIPK3—islet of Langerhans—pancreatic cancer	0.000344	0.00858	CbGeAlD
Sunitinib—DAPK3—islet of Langerhans—pancreatic cancer	0.00033	0.00824	CbGeAlD
Sunitinib—DAPK1—pancreas—pancreatic cancer	0.000326	0.00813	CbGeAlD
Sunitinib—STK11—pancreas—pancreatic cancer	0.000316	0.00788	CbGeAlD
Sunitinib—BRD4—pancreas—pancreatic cancer	0.000316	0.00788	CbGeAlD
Sunitinib—RPS6KA1—pancreas—pancreatic cancer	0.000312	0.0078	CbGeAlD
Sunitinib—STK17A—digestive system—pancreatic cancer	0.000312	0.00779	CbGeAlD
Sunitinib—CDK16—digestive system—pancreatic cancer	0.000303	0.00757	CbGeAlD
Sunitinib—STK33—digestive system—pancreatic cancer	0.000299	0.00747	CbGeAlD
Sunitinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000298	0.00111	CbGbCtD
Sunitinib—MAP4K4—islet of Langerhans—pancreatic cancer	0.000296	0.0074	CbGeAlD
Sunitinib—PDGFRA—gall bladder—pancreatic cancer	0.000295	0.00736	CbGeAlD
Sunitinib—NUAK2—islet of Langerhans—pancreatic cancer	0.000294	0.00735	CbGeAlD
Sunitinib—NUAK1—pancreas—pancreatic cancer	0.00029	0.00725	CbGeAlD
Sunitinib—RPS6KA3—islet of Langerhans—pancreatic cancer	0.000288	0.00719	CbGeAlD
Sunitinib—OXSR1—pancreas—pancreatic cancer	0.000288	0.00719	CbGeAlD
Sunitinib—INSR—pancreas—pancreatic cancer	0.000288	0.00719	CbGeAlD
Sunitinib—STK38—pancreas—pancreatic cancer	0.000283	0.00707	CbGeAlD
Sunitinib—RPS6KA2—pancreas—pancreatic cancer	0.000283	0.00707	CbGeAlD
Sunitinib—CSNK1A1—islet of Langerhans—pancreatic cancer	0.000283	0.00705	CbGeAlD
Sunitinib—CLK1—islet of Langerhans—pancreatic cancer	0.000281	0.00701	CbGeAlD
Sunitinib—CSNK1G2—pancreas—pancreatic cancer	0.000279	0.00697	CbGeAlD
Sunitinib—DAPK1—digestive system—pancreatic cancer	0.000278	0.00694	CbGeAlD
Sunitinib—PRPF4—pancreas—pancreatic cancer	0.000275	0.00686	CbGeAlD
Sunitinib—PRPF4B—pancreas—pancreatic cancer	0.000271	0.00677	CbGeAlD
Sunitinib—BRD4—digestive system—pancreatic cancer	0.000269	0.00673	CbGeAlD
Sunitinib—STK11—digestive system—pancreatic cancer	0.000269	0.00673	CbGeAlD
Sunitinib—PRKAA1—islet of Langerhans—pancreatic cancer	0.000269	0.00672	CbGeAlD
Sunitinib—STK39—pancreas—pancreatic cancer	0.000267	0.00667	CbGeAlD
Sunitinib—DYRK1A—Topotecan—Irinotecan—pancreatic cancer	0.000265	0.166	CbGdCrCtD
Sunitinib—CSNK2A1—pancreas—pancreatic cancer	0.000264	0.00658	CbGeAlD
Sunitinib—CSNK1E—islet of Langerhans—pancreatic cancer	0.000262	0.00654	CbGeAlD
Sunitinib—MARK2—digestive system—pancreatic cancer	0.000262	0.00653	CbGeAlD
Sunitinib—MYLK—pancreas—pancreatic cancer	0.00026	0.0065	CbGeAlD
Sunitinib—IRAK4—islet of Langerhans—pancreatic cancer	0.000258	0.00643	CbGeAlD
Sunitinib—MAP2K2—islet of Langerhans—pancreatic cancer	0.000252	0.00629	CbGeAlD
Sunitinib—INSR—digestive system—pancreatic cancer	0.000246	0.00614	CbGeAlD
Sunitinib—TBK1—islet of Langerhans—pancreatic cancer	0.000245	0.00612	CbGeAlD
Sunitinib—TYK2—islet of Langerhans—pancreatic cancer	0.000243	0.00608	CbGeAlD
Sunitinib—STK38—digestive system—pancreatic cancer	0.000242	0.00604	CbGeAlD
Sunitinib—HIPK3—pancreas—pancreatic cancer	0.000242	0.00603	CbGeAlD
Sunitinib—HIPK2—pancreas—pancreatic cancer	0.000242	0.00603	CbGeAlD
Sunitinib—IRAK1—islet of Langerhans—pancreatic cancer	0.00024	0.006	CbGeAlD
Sunitinib—CSNK1G2—digestive system—pancreatic cancer	0.000238	0.00595	CbGeAlD
Sunitinib—PKN1—digestive system—pancreatic cancer	0.000238	0.00595	CbGeAlD
Sunitinib—KIT—gall bladder—pancreatic cancer	0.000236	0.00589	CbGeAlD
Sunitinib—PRPF4—digestive system—pancreatic cancer	0.000235	0.00586	CbGeAlD
Sunitinib—DAPK3—pancreas—pancreatic cancer	0.000232	0.00579	CbGeAlD
Sunitinib—PRPF4B—digestive system—pancreatic cancer	0.000232	0.00578	CbGeAlD
Sunitinib—PDGFRB—gall bladder—pancreatic cancer	0.00023	0.00575	CbGeAlD
Sunitinib—CSNK2A1—digestive system—pancreatic cancer	0.000225	0.00562	CbGeAlD
Sunitinib—SLK—islet of Langerhans—pancreatic cancer	0.000225	0.00561	CbGeAlD
Sunitinib—MYLK—digestive system—pancreatic cancer	0.000222	0.00555	CbGeAlD
Sunitinib—STK4—digestive system—pancreatic cancer	0.000218	0.00545	CbGeAlD
Sunitinib—MAP4K5—islet of Langerhans—pancreatic cancer	0.000213	0.00533	CbGeAlD
Sunitinib—MAP4K4—pancreas—pancreatic cancer	0.000208	0.0052	CbGeAlD
Sunitinib—STK16—digestive system—pancreatic cancer	0.000207	0.00518	CbGeAlD
Sunitinib—NUAK2—pancreas—pancreatic cancer	0.000207	0.00516	CbGeAlD
Sunitinib—FLT1—islet of Langerhans—pancreatic cancer	0.000206	0.00515	CbGeAlD
Sunitinib—HIPK2—digestive system—pancreatic cancer	0.000206	0.00515	CbGeAlD
Sunitinib—HIPK3—digestive system—pancreatic cancer	0.000206	0.00515	CbGeAlD
Sunitinib—ALK—digestive system—pancreatic cancer	0.000206	0.00515	CbGeAlD
Sunitinib—EPHB6—islet of Langerhans—pancreatic cancer	0.000204	0.00509	CbGeAlD
Sunitinib—RPS6KA3—pancreas—pancreatic cancer	0.000203	0.00506	CbGeAlD
Sunitinib—CSNK1A1—pancreas—pancreatic cancer	0.000199	0.00496	CbGeAlD
Sunitinib—CLK1—pancreas—pancreatic cancer	0.000197	0.00493	CbGeAlD
Sunitinib—YES1—islet of Langerhans—pancreatic cancer	0.000197	0.00492	CbGeAlD
Sunitinib—TAOK3—islet of Langerhans—pancreatic cancer	0.000195	0.00486	CbGeAlD
Sunitinib—CAMK2G—pancreas—pancreatic cancer	0.000194	0.00484	CbGeAlD
Sunitinib—ROCK1—digestive system—pancreatic cancer	0.00019	0.00475	CbGeAlD
Sunitinib—PRKAA1—pancreas—pancreatic cancer	0.000189	0.00472	CbGeAlD
Sunitinib—CSNK1E—pancreas—pancreatic cancer	0.000184	0.00459	CbGeAlD
Sunitinib—PLK4—Topotecan—Irinotecan—pancreatic cancer	0.000181	0.113	CbGdCrCtD
Sunitinib—MAP4K4—digestive system—pancreatic cancer	0.000178	0.00444	CbGeAlD
Sunitinib—MAP2K2—pancreas—pancreatic cancer	0.000177	0.00442	CbGeAlD
Sunitinib—TBK1—pancreas—pancreatic cancer	0.000172	0.0043	CbGeAlD
Sunitinib—MAP2K1—digestive system—pancreatic cancer	0.000172	0.00429	CbGeAlD
Sunitinib—TYK2—pancreas—pancreatic cancer	0.000171	0.00427	CbGeAlD
Sunitinib—CSNK1A1—digestive system—pancreatic cancer	0.00017	0.00423	CbGeAlD
Sunitinib—IRAK1—pancreas—pancreatic cancer	0.000169	0.00422	CbGeAlD
Sunitinib—CLK1—digestive system—pancreatic cancer	0.000169	0.00421	CbGeAlD
Sunitinib—RPS6KB1—pancreas—pancreatic cancer	0.000166	0.00414	CbGeAlD
Sunitinib—CAMK2G—digestive system—pancreatic cancer	0.000165	0.00413	CbGeAlD
Sunitinib—PRKAA1—digestive system—pancreatic cancer	0.000162	0.00403	CbGeAlD
Sunitinib—PTK2B—digestive system—pancreatic cancer	0.00016	0.00399	CbGeAlD
Sunitinib—SLK—pancreas—pancreatic cancer	0.000158	0.00394	CbGeAlD
Sunitinib—CSNK1E—digestive system—pancreatic cancer	0.000157	0.00392	CbGeAlD
Sunitinib—ULK3—digestive system—pancreatic cancer	0.000151	0.00378	CbGeAlD
Sunitinib—MAP2K2—digestive system—pancreatic cancer	0.000151	0.00378	CbGeAlD
Sunitinib—PDGFRB—islet of Langerhans—pancreatic cancer	0.000151	0.00377	CbGeAlD
Sunitinib—MAP4K5—pancreas—pancreatic cancer	0.00015	0.00375	CbGeAlD
Sunitinib—TBK1—digestive system—pancreatic cancer	0.000147	0.00367	CbGeAlD
Sunitinib—TYK2—digestive system—pancreatic cancer	0.000146	0.00365	CbGeAlD
Sunitinib—FLT1—pancreas—pancreatic cancer	0.000145	0.00362	CbGeAlD
Sunitinib—RPS6KB1—digestive system—pancreatic cancer	0.000142	0.00353	CbGeAlD
Sunitinib—FGR—digestive system—pancreatic cancer	0.000141	0.00351	CbGeAlD
Sunitinib—RET—digestive system—pancreatic cancer	0.000141	0.00351	CbGeAlD
Sunitinib—YES1—pancreas—pancreatic cancer	0.000139	0.00346	CbGeAlD
Sunitinib—TAOK3—pancreas—pancreatic cancer	0.000137	0.00341	CbGeAlD
Sunitinib—FGFR2—digestive system—pancreatic cancer	0.000134	0.00334	CbGeAlD
Sunitinib—JAK2—digestive system—pancreatic cancer	0.000133	0.00332	CbGeAlD
Sunitinib—FYN—digestive system—pancreatic cancer	0.000131	0.00327	CbGeAlD
Sunitinib—FLT1—digestive system—pancreatic cancer	0.000124	0.00309	CbGeAlD
Sunitinib—YES1—digestive system—pancreatic cancer	0.000118	0.00295	CbGeAlD
Sunitinib—STK10—digestive system—pancreatic cancer	0.000117	0.00293	CbGeAlD
Sunitinib—TAOK3—digestive system—pancreatic cancer	0.000117	0.00292	CbGeAlD
Sunitinib—PDGFRA—digestive system—pancreatic cancer	0.000116	0.0029	CbGeAlD
Sunitinib—CAMK2G—Azacitidine—Gemcitabine—pancreatic cancer	0.000116	0.0725	CbGdCrCtD
Sunitinib—CHEK2—Paclitaxel—Docetaxel—pancreatic cancer	0.000112	0.07	CbGdCrCtD
Sunitinib—KIT—pancreas—pancreatic cancer	0.000109	0.00271	CbGeAlD
Sunitinib—PDGFRB—pancreas—pancreatic cancer	0.000106	0.00265	CbGeAlD
Sunitinib—KDR—digestive system—pancreatic cancer	0.000105	0.00261	CbGeAlD
Sunitinib—CSF1R—digestive system—pancreatic cancer	0.000102	0.00255	CbGeAlD
Sunitinib—KCNH2—islet of Langerhans—pancreatic cancer	9.54e-05	0.00238	CbGeAlD
Sunitinib—KIT—digestive system—pancreatic cancer	9.28e-05	0.00232	CbGeAlD
Sunitinib—PDGFRB—digestive system—pancreatic cancer	9.07e-05	0.00226	CbGeAlD
Sunitinib—ABCC4—pancreas—pancreatic cancer	8.45e-05	0.00211	CbGeAlD
Sunitinib—CYP3A5—islet of Langerhans—pancreatic cancer	7.88e-05	0.00197	CbGeAlD
Sunitinib—ABCC4—digestive system—pancreatic cancer	7.22e-05	0.0018	CbGeAlD
Sunitinib—ABCC2—digestive system—pancreatic cancer	6.99e-05	0.00174	CbGeAlD
Sunitinib—PRPF4—Promazine—Tamoxifen—pancreatic cancer	6.27e-05	0.0392	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—pancreatic cancer	6.23e-05	0.039	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—pancreatic cancer	6.23e-05	0.039	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—pancreatic cancer	6.23e-05	0.039	CbGdCrCtD
Sunitinib—RPS6KA1—Azacitidine—Gemcitabine—pancreatic cancer	5.94e-05	0.0371	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—pancreatic cancer	5.77e-05	0.036	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—pancreatic cancer	5.77e-05	0.036	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—pancreatic cancer	5.77e-05	0.036	CbGdCrCtD
Sunitinib—CYP3A5—pancreas—pancreatic cancer	5.54e-05	0.00138	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—pancreatic cancer	5.38e-05	0.0336	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—pancreatic cancer	5.38e-05	0.0336	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—pancreatic cancer	4.98e-05	0.0311	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—pancreatic cancer	4.98e-05	0.0311	CbGdCrCtD
Sunitinib—CYP3A5—digestive system—pancreatic cancer	4.73e-05	0.00118	CbGeAlD
Sunitinib—PLK4—Doxorubicin—Epirubicin—pancreatic cancer	4.26e-05	0.0266	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Epirubicin—pancreatic cancer	4.26e-05	0.0266	CbGdCrCtD
Sunitinib—ABCB1—islet of Langerhans—pancreatic cancer	4.19e-05	0.00104	CbGeAlD
Sunitinib—PLK4—Idarubicin—Doxorubicin—pancreatic cancer	3.94e-05	0.0246	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—pancreatic cancer	3.94e-05	0.0246	CbGdCrCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—pancreatic cancer	3.75e-05	0.0235	CbGdCrCtD
Sunitinib—CYP3A4—digestive system—pancreatic cancer	3.55e-05	0.000886	CbGeAlD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—pancreatic cancer	3.47e-05	0.0217	CbGdCrCtD
Sunitinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	3.11e-05	0.000487	CcSEcCtD
Sunitinib—Dehydration—Doxorubicin—pancreatic cancer	3.11e-05	0.000486	CcSEcCtD
Sunitinib—Muscle spasms—Docetaxel—pancreatic cancer	3.1e-05	0.000485	CcSEcCtD
Sunitinib—Liver function test abnormal—Doxorubicin—pancreatic cancer	3.09e-05	0.000482	CcSEcCtD
Sunitinib—Dry skin—Doxorubicin—pancreatic cancer	3.06e-05	0.000479	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—pancreatic cancer	3.06e-05	0.000479	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—pancreatic cancer	3.05e-05	0.000477	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—pancreatic cancer	3.04e-05	0.000476	CcSEcCtD
Sunitinib—Abdominal pain—Irinotecan—pancreatic cancer	3.01e-05	0.000471	CcSEcCtD
Sunitinib—Body temperature increased—Irinotecan—pancreatic cancer	3.01e-05	0.000471	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	3.01e-05	0.000471	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	3.01e-05	0.000471	CcSEcCtD
Sunitinib—Bronchitis—Epirubicin—pancreatic cancer	3e-05	0.000469	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—pancreatic cancer	2.99e-05	0.000467	CcSEcCtD
Sunitinib—Anaemia—Docetaxel—pancreatic cancer	2.98e-05	0.000466	CcSEcCtD
Sunitinib—Pancytopenia—Epirubicin—pancreatic cancer	2.97e-05	0.000464	CcSEcCtD
Sunitinib—Muscular weakness—Doxorubicin—pancreatic cancer	2.95e-05	0.000461	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	2.95e-05	0.000461	CcSEcCtD
Sunitinib—ABCB1—pancreas—pancreatic cancer	2.94e-05	0.000734	CbGeAlD
Sunitinib—Body temperature increased—Gemcitabine—pancreatic cancer	2.93e-05	0.000458	CcSEcCtD
Sunitinib—Neutropenia—Epirubicin—pancreatic cancer	2.92e-05	0.000456	CcSEcCtD
Sunitinib—Abdominal distension—Doxorubicin—pancreatic cancer	2.91e-05	0.000455	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—pancreatic cancer	2.9e-05	0.000454	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—pancreatic cancer	2.89e-05	0.000452	CcSEcCtD
Sunitinib—Leukopenia—Docetaxel—pancreatic cancer	2.89e-05	0.000451	CcSEcCtD
Sunitinib—Body temperature increased—Fluorouracil—pancreatic cancer	2.88e-05	0.000451	CcSEcCtD
Sunitinib—Pancreatitis—Doxorubicin—pancreatic cancer	2.83e-05	0.000443	CcSEcCtD
Sunitinib—Weight decreased—Epirubicin—pancreatic cancer	2.83e-05	0.000442	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—pancreatic cancer	2.82e-05	0.00044	CcSEcCtD
Sunitinib—Cough—Docetaxel—pancreatic cancer	2.81e-05	0.00044	CcSEcCtD
Sunitinib—Hypersensitivity—Irinotecan—pancreatic cancer	2.81e-05	0.000439	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—pancreatic cancer	2.8e-05	0.000438	CcSEcCtD
Sunitinib—Convulsion—Docetaxel—pancreatic cancer	2.8e-05	0.000437	CcSEcCtD
Sunitinib—Hypertension—Docetaxel—pancreatic cancer	2.79e-05	0.000435	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—pancreatic cancer	2.78e-05	0.000435	CcSEcCtD
Sunitinib—Infestation—Epirubicin—pancreatic cancer	2.78e-05	0.000435	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—pancreatic cancer	2.78e-05	0.000434	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	2.76e-05	0.000431	CcSEcCtD
Sunitinib—Myalgia—Docetaxel—pancreatic cancer	2.75e-05	0.000429	CcSEcCtD
Sunitinib—Chest pain—Docetaxel—pancreatic cancer	2.75e-05	0.000429	CcSEcCtD
Sunitinib—Arthralgia—Docetaxel—pancreatic cancer	2.75e-05	0.000429	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—pancreatic cancer	2.74e-05	0.000429	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—pancreatic cancer	2.74e-05	0.000428	CcSEcCtD
Sunitinib—Asthenia—Irinotecan—pancreatic cancer	2.73e-05	0.000427	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—pancreatic cancer	2.73e-05	0.000427	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	2.73e-05	0.000426	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—pancreatic cancer	2.71e-05	0.000424	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—pancreatic cancer	2.71e-05	0.000423	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—pancreatic cancer	2.7e-05	0.000422	CcSEcCtD
Sunitinib—Hypersensitivity—Fluorouracil—pancreatic cancer	2.69e-05	0.00042	CcSEcCtD
Sunitinib—Dry mouth—Docetaxel—pancreatic cancer	2.69e-05	0.00042	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	2.69e-05	0.00042	CcSEcCtD
Sunitinib—Asthenia—Gemcitabine—pancreatic cancer	2.66e-05	0.000416	CcSEcCtD
Sunitinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.63e-05	0.000412	CcSEcCtD
Sunitinib—Oedema—Docetaxel—pancreatic cancer	2.63e-05	0.000412	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—pancreatic cancer	2.63e-05	0.00041	CcSEcCtD
Sunitinib—Pruritus—Gemcitabine—pancreatic cancer	2.62e-05	0.00041	CcSEcCtD
Sunitinib—Infection—Docetaxel—pancreatic cancer	2.62e-05	0.000409	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—pancreatic cancer	2.61e-05	0.000409	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—pancreatic cancer	2.61e-05	0.000407	CcSEcCtD
Sunitinib—Diarrhoea—Irinotecan—pancreatic cancer	2.61e-05	0.000407	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—pancreatic cancer	2.59e-05	0.000405	CcSEcCtD
Sunitinib—Shock—Docetaxel—pancreatic cancer	2.59e-05	0.000405	CcSEcCtD
Sunitinib—Nervous system disorder—Docetaxel—pancreatic cancer	2.58e-05	0.000404	CcSEcCtD
Sunitinib—Pruritus—Fluorouracil—pancreatic cancer	2.58e-05	0.000403	CcSEcCtD
Sunitinib—Thrombocytopenia—Docetaxel—pancreatic cancer	2.58e-05	0.000403	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—pancreatic cancer	2.58e-05	0.000403	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—pancreatic cancer	2.58e-05	0.000403	CcSEcCtD
Sunitinib—Skin disorder—Docetaxel—pancreatic cancer	2.56e-05	0.0004	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	2.55e-05	0.000399	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—pancreatic cancer	2.54e-05	0.000398	CcSEcCtD
Sunitinib—Diarrhoea—Gemcitabine—pancreatic cancer	2.54e-05	0.000397	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—pancreatic cancer	2.53e-05	0.000396	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	2.53e-05	0.000395	CcSEcCtD
Sunitinib—Dizziness—Irinotecan—pancreatic cancer	2.52e-05	0.000394	CcSEcCtD
Sunitinib—ABCB1—digestive system—pancreatic cancer	2.51e-05	0.000627	CbGeAlD
Sunitinib—Haemoglobin—Epirubicin—pancreatic cancer	2.51e-05	0.000393	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—pancreatic cancer	2.51e-05	0.000393	CcSEcCtD
Sunitinib—Anorexia—Docetaxel—pancreatic cancer	2.51e-05	0.000392	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—pancreatic cancer	2.5e-05	0.000391	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—pancreatic cancer	2.5e-05	0.000391	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—pancreatic cancer	2.5e-05	0.000391	CcSEcCtD
Sunitinib—Diarrhoea—Fluorouracil—pancreatic cancer	2.5e-05	0.00039	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—pancreatic cancer	2.49e-05	0.000389	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—pancreatic cancer	2.47e-05	0.000386	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—pancreatic cancer	2.46e-05	0.000385	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—pancreatic cancer	2.46e-05	0.000384	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—pancreatic cancer	2.45e-05	0.000383	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.44e-05	0.000381	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—pancreatic cancer	2.43e-05	0.00038	CcSEcCtD
Sunitinib—Vomiting—Irinotecan—pancreatic cancer	2.42e-05	0.000378	CcSEcCtD
Sunitinib—Dizziness—Fluorouracil—pancreatic cancer	2.41e-05	0.000377	CcSEcCtD
Sunitinib—Rash—Irinotecan—pancreatic cancer	2.4e-05	0.000375	CcSEcCtD
Sunitinib—Dermatitis—Irinotecan—pancreatic cancer	2.4e-05	0.000375	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	2.4e-05	0.000375	CcSEcCtD
Sunitinib—Headache—Irinotecan—pancreatic cancer	2.39e-05	0.000373	CcSEcCtD
Sunitinib—Insomnia—Docetaxel—pancreatic cancer	2.38e-05	0.000372	CcSEcCtD
Sunitinib—Paraesthesia—Docetaxel—pancreatic cancer	2.36e-05	0.00037	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—pancreatic cancer	2.36e-05	0.000369	CcSEcCtD
Sunitinib—Vomiting—Gemcitabine—pancreatic cancer	2.36e-05	0.000369	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—pancreatic cancer	2.35e-05	0.000368	CcSEcCtD
Sunitinib—Dyspnoea—Docetaxel—pancreatic cancer	2.35e-05	0.000367	CcSEcCtD
Sunitinib—Rash—Gemcitabine—pancreatic cancer	2.34e-05	0.000366	CcSEcCtD
Sunitinib—Dermatitis—Gemcitabine—pancreatic cancer	2.34e-05	0.000365	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—pancreatic cancer	2.34e-05	0.000365	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—pancreatic cancer	2.32e-05	0.000363	CcSEcCtD
Sunitinib—Headache—Gemcitabine—pancreatic cancer	2.32e-05	0.000363	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—pancreatic cancer	2.32e-05	0.000363	CcSEcCtD
Sunitinib—Flushing—Epirubicin—pancreatic cancer	2.32e-05	0.000363	CcSEcCtD
Sunitinib—Vomiting—Fluorouracil—pancreatic cancer	2.32e-05	0.000363	CcSEcCtD
Sunitinib—Dyspepsia—Docetaxel—pancreatic cancer	2.32e-05	0.000362	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—pancreatic cancer	2.31e-05	0.000361	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—pancreatic cancer	2.31e-05	0.000361	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—pancreatic cancer	2.3e-05	0.00036	CcSEcCtD
Sunitinib—Rash—Fluorouracil—pancreatic cancer	2.3e-05	0.000359	CcSEcCtD
Sunitinib—Dermatitis—Fluorouracil—pancreatic cancer	2.3e-05	0.000359	CcSEcCtD
Sunitinib—Decreased appetite—Docetaxel—pancreatic cancer	2.29e-05	0.000358	CcSEcCtD
Sunitinib—Headache—Fluorouracil—pancreatic cancer	2.29e-05	0.000357	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.28e-05	0.000357	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—pancreatic cancer	2.28e-05	0.000356	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.27e-05	0.000355	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	2.27e-05	0.000355	CcSEcCtD
Sunitinib—Fatigue—Docetaxel—pancreatic cancer	2.27e-05	0.000355	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—pancreatic cancer	2.27e-05	0.000354	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—pancreatic cancer	2.27e-05	0.000354	CcSEcCtD
Sunitinib—Nausea—Irinotecan—pancreatic cancer	2.26e-05	0.000354	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—pancreatic cancer	2.26e-05	0.000353	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—pancreatic cancer	2.25e-05	0.000352	CcSEcCtD
Sunitinib—Pain—Docetaxel—pancreatic cancer	2.25e-05	0.000352	CcSEcCtD
Sunitinib—Constipation—Docetaxel—pancreatic cancer	2.25e-05	0.000352	CcSEcCtD
Sunitinib—Chills—Epirubicin—pancreatic cancer	2.24e-05	0.000351	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—pancreatic cancer	2.23e-05	0.000349	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—pancreatic cancer	2.21e-05	0.000345	CcSEcCtD
Sunitinib—Nausea—Gemcitabine—pancreatic cancer	2.2e-05	0.000344	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—pancreatic cancer	2.19e-05	0.000342	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—pancreatic cancer	2.19e-05	0.000342	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—pancreatic cancer	2.18e-05	0.00034	CcSEcCtD
Sunitinib—Erythema—Epirubicin—pancreatic cancer	2.18e-05	0.00034	CcSEcCtD
Sunitinib—Nausea—Fluorouracil—pancreatic cancer	2.17e-05	0.000339	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—pancreatic cancer	2.16e-05	0.000338	CcSEcCtD
Sunitinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	2.15e-05	0.000336	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—pancreatic cancer	2.15e-05	0.000335	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—pancreatic cancer	2.15e-05	0.000335	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—pancreatic cancer	2.14e-05	0.000335	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—pancreatic cancer	2.13e-05	0.000333	CcSEcCtD
Sunitinib—Back pain—Epirubicin—pancreatic cancer	2.1e-05	0.000329	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—pancreatic cancer	2.1e-05	0.000328	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—pancreatic cancer	2.09e-05	0.000327	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—pancreatic cancer	2.09e-05	0.000327	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.08e-05	0.000326	CcSEcCtD
Sunitinib—Abdominal pain—Docetaxel—pancreatic cancer	2.08e-05	0.000325	CcSEcCtD
Sunitinib—Body temperature increased—Docetaxel—pancreatic cancer	2.08e-05	0.000325	CcSEcCtD
Sunitinib—Chills—Doxorubicin—pancreatic cancer	2.08e-05	0.000324	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—pancreatic cancer	2.07e-05	0.000323	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—pancreatic cancer	2.04e-05	0.000319	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—pancreatic cancer	2.03e-05	0.000317	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—pancreatic cancer	2.01e-05	0.000315	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—pancreatic cancer	2.01e-05	0.000315	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—pancreatic cancer	2.01e-05	0.000314	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—pancreatic cancer	1.98e-05	0.00031	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—pancreatic cancer	1.97e-05	0.000308	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—pancreatic cancer	1.95e-05	0.000304	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—pancreatic cancer	1.95e-05	0.000304	CcSEcCtD
Sunitinib—Hypersensitivity—Docetaxel—pancreatic cancer	1.94e-05	0.000303	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—pancreatic cancer	1.94e-05	0.000303	CcSEcCtD
Sunitinib—Cough—Epirubicin—pancreatic cancer	1.9e-05	0.000297	CcSEcCtD
Sunitinib—Asthenia—Docetaxel—pancreatic cancer	1.89e-05	0.000295	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—pancreatic cancer	1.89e-05	0.000295	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—pancreatic cancer	1.88e-05	0.000294	CcSEcCtD
Sunitinib—Pruritus—Docetaxel—pancreatic cancer	1.86e-05	0.000291	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—pancreatic cancer	1.86e-05	0.000291	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—pancreatic cancer	1.85e-05	0.00029	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—pancreatic cancer	1.85e-05	0.00029	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—pancreatic cancer	1.85e-05	0.00029	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.84e-05	0.000288	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—pancreatic cancer	1.81e-05	0.000283	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—pancreatic cancer	1.8e-05	0.000282	CcSEcCtD
Sunitinib—Diarrhoea—Docetaxel—pancreatic cancer	1.8e-05	0.000282	CcSEcCtD
Sunitinib—Oedema—Epirubicin—pancreatic cancer	1.78e-05	0.000278	CcSEcCtD
Sunitinib—Infection—Epirubicin—pancreatic cancer	1.76e-05	0.000276	CcSEcCtD
Sunitinib—Cough—Doxorubicin—pancreatic cancer	1.76e-05	0.000275	CcSEcCtD
Sunitinib—Shock—Epirubicin—pancreatic cancer	1.75e-05	0.000273	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—pancreatic cancer	1.74e-05	0.000273	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—pancreatic cancer	1.74e-05	0.000272	CcSEcCtD
Sunitinib—Dizziness—Docetaxel—pancreatic cancer	1.74e-05	0.000272	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—pancreatic cancer	1.74e-05	0.000272	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—pancreatic cancer	1.74e-05	0.000272	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—pancreatic cancer	1.72e-05	0.00027	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—pancreatic cancer	1.71e-05	0.000268	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—pancreatic cancer	1.71e-05	0.000268	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—pancreatic cancer	1.71e-05	0.000268	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.7e-05	0.000266	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—pancreatic cancer	1.69e-05	0.000265	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—pancreatic cancer	1.68e-05	0.000262	CcSEcCtD
Sunitinib—Vomiting—Docetaxel—pancreatic cancer	1.67e-05	0.000262	CcSEcCtD
Sunitinib—Rash—Docetaxel—pancreatic cancer	1.66e-05	0.000259	CcSEcCtD
Sunitinib—Dermatitis—Docetaxel—pancreatic cancer	1.66e-05	0.000259	CcSEcCtD
Sunitinib—Headache—Docetaxel—pancreatic cancer	1.65e-05	0.000258	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—pancreatic cancer	1.64e-05	0.000257	CcSEcCtD
Sunitinib—Infection—Doxorubicin—pancreatic cancer	1.63e-05	0.000255	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.62e-05	0.000253	CcSEcCtD
Sunitinib—Shock—Doxorubicin—pancreatic cancer	1.62e-05	0.000253	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—pancreatic cancer	1.61e-05	0.000252	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.61e-05	0.000251	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—pancreatic cancer	1.61e-05	0.000251	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—pancreatic cancer	1.6e-05	0.000249	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—pancreatic cancer	1.59e-05	0.000249	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—pancreatic cancer	1.58e-05	0.000247	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—pancreatic cancer	1.57e-05	0.000245	CcSEcCtD
Sunitinib—Nausea—Docetaxel—pancreatic cancer	1.56e-05	0.000244	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—pancreatic cancer	1.56e-05	0.000244	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—pancreatic cancer	1.54e-05	0.000241	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.53e-05	0.00024	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—pancreatic cancer	1.53e-05	0.000239	CcSEcCtD
Sunitinib—Pain—Epirubicin—pancreatic cancer	1.52e-05	0.000237	CcSEcCtD
Sunitinib—Constipation—Epirubicin—pancreatic cancer	1.52e-05	0.000237	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.5e-05	0.000234	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—pancreatic cancer	1.49e-05	0.000232	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—pancreatic cancer	1.48e-05	0.000231	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—pancreatic cancer	1.46e-05	0.000229	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.45e-05	0.000227	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—pancreatic cancer	1.45e-05	0.000226	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—pancreatic cancer	1.43e-05	0.000223	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.42e-05	0.000222	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—pancreatic cancer	1.42e-05	0.000221	CcSEcCtD
Sunitinib—Pain—Doxorubicin—pancreatic cancer	1.41e-05	0.00022	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—pancreatic cancer	1.41e-05	0.00022	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—pancreatic cancer	1.4e-05	0.000219	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—pancreatic cancer	1.4e-05	0.000219	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.34e-05	0.00021	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—pancreatic cancer	1.31e-05	0.000204	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.3e-05	0.000203	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—pancreatic cancer	1.3e-05	0.000203	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—pancreatic cancer	1.27e-05	0.000199	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—pancreatic cancer	1.26e-05	0.000196	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—pancreatic cancer	1.22e-05	0.00019	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—pancreatic cancer	1.21e-05	0.000189	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—pancreatic cancer	1.18e-05	0.000184	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—pancreatic cancer	1.17e-05	0.000184	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—pancreatic cancer	1.16e-05	0.000182	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—pancreatic cancer	1.13e-05	0.000176	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.12e-05	0.000176	CcSEcCtD
Sunitinib—Rash—Epirubicin—pancreatic cancer	1.12e-05	0.000175	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—pancreatic cancer	1.12e-05	0.000175	CcSEcCtD
Sunitinib—Headache—Epirubicin—pancreatic cancer	1.11e-05	0.000174	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—pancreatic cancer	1.09e-05	0.00017	CcSEcCtD
Sunitinib—Nausea—Epirubicin—pancreatic cancer	1.05e-05	0.000165	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—pancreatic cancer	1.04e-05	0.000163	CcSEcCtD
Sunitinib—Rash—Doxorubicin—pancreatic cancer	1.04e-05	0.000162	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—pancreatic cancer	1.04e-05	0.000162	CcSEcCtD
Sunitinib—Headache—Doxorubicin—pancreatic cancer	1.03e-05	0.000161	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—pancreatic cancer	9.76e-06	0.000153	CcSEcCtD
Sunitinib—MAP2K2—Signaling Pathways—CTNNB1—pancreatic cancer	3.07e-07	3.4e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—pancreatic cancer	3.07e-07	3.4e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—pancreatic cancer	3.07e-07	3.4e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—STAT3—pancreatic cancer	3.06e-07	3.39e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—STAT3—pancreatic cancer	3.06e-07	3.39e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—pancreatic cancer	3.06e-07	3.39e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—pancreatic cancer	3.06e-07	3.39e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—PIK3CA—pancreatic cancer	3.06e-07	3.38e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—pancreatic cancer	3.05e-07	3.38e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—pancreatic cancer	3.05e-07	3.38e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—pancreatic cancer	3.05e-07	3.38e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—pancreatic cancer	3.03e-07	3.36e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—pancreatic cancer	3.03e-07	3.35e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—pancreatic cancer	3.02e-07	3.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—pancreatic cancer	3.02e-07	3.35e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—pancreatic cancer	3.02e-07	3.35e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—TYMS—pancreatic cancer	3.02e-07	3.35e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TGFB1—pancreatic cancer	3.02e-07	3.34e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PIK3CA—pancreatic cancer	3.02e-07	3.34e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—pancreatic cancer	3.02e-07	3.34e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—SRC—pancreatic cancer	3.01e-07	3.34e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—pancreatic cancer	3.01e-07	3.34e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—SRC—pancreatic cancer	3.01e-07	3.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CTNNB1—pancreatic cancer	3e-07	3.32e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CASP3—pancreatic cancer	3e-07	3.32e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PTEN—pancreatic cancer	2.99e-07	3.32e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CASP3—pancreatic cancer	2.98e-07	3.3e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL8—pancreatic cancer	2.98e-07	3.3e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	2.96e-07	3.28e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—pancreatic cancer	2.96e-07	3.28e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—pancreatic cancer	2.96e-07	3.28e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EGFR—pancreatic cancer	2.96e-07	3.28e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—pancreatic cancer	2.95e-07	3.27e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—pancreatic cancer	2.95e-07	3.26e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PIK3CA—pancreatic cancer	2.94e-07	3.26e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	2.94e-07	3.26e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—pancreatic cancer	2.94e-07	3.25e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—pancreatic cancer	2.94e-07	3.25e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—pancreatic cancer	2.94e-07	3.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—pancreatic cancer	2.94e-07	3.25e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—pancreatic cancer	2.93e-07	3.24e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—pancreatic cancer	2.93e-07	3.24e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	2.92e-07	3.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—PIK3CA—pancreatic cancer	2.92e-07	3.23e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—pancreatic cancer	2.92e-07	3.23e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—pancreatic cancer	2.92e-07	3.23e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STAT3—pancreatic cancer	2.91e-07	3.22e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—pancreatic cancer	2.91e-07	3.22e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—pancreatic cancer	2.9e-07	3.21e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—pancreatic cancer	2.9e-07	3.21e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—pancreatic cancer	2.9e-07	3.21e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—pancreatic cancer	2.9e-07	3.21e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—pancreatic cancer	2.9e-07	3.21e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—pancreatic cancer	2.89e-07	3.2e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—pancreatic cancer	2.89e-07	3.2e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—pancreatic cancer	2.89e-07	3.2e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—pancreatic cancer	2.89e-07	3.2e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—pancreatic cancer	2.88e-07	3.19e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—pancreatic cancer	2.88e-07	3.18e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—pancreatic cancer	2.87e-07	3.18e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—pancreatic cancer	2.87e-07	3.18e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—pancreatic cancer	2.87e-07	3.18e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—pancreatic cancer	2.85e-07	3.16e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—pancreatic cancer	2.85e-07	3.15e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—pancreatic cancer	2.85e-07	3.15e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—pancreatic cancer	2.84e-07	3.15e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—pancreatic cancer	2.84e-07	3.15e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—pancreatic cancer	2.84e-07	3.15e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—pancreatic cancer	2.84e-07	3.14e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	2.84e-07	3.14e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—pancreatic cancer	2.84e-07	3.14e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—pancreatic cancer	2.83e-07	3.14e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—pancreatic cancer	2.83e-07	3.13e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—pancreatic cancer	2.82e-07	3.13e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—pancreatic cancer	2.82e-07	3.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—pancreatic cancer	2.82e-07	3.12e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—pancreatic cancer	2.82e-07	3.12e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—pancreatic cancer	2.82e-07	3.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—pancreatic cancer	2.8e-07	3.1e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—pancreatic cancer	2.79e-07	3.09e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—pancreatic cancer	2.79e-07	3.09e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—pancreatic cancer	2.78e-07	3.08e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—pancreatic cancer	2.78e-07	3.08e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—SRC—pancreatic cancer	2.78e-07	3.07e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—pancreatic cancer	2.77e-07	3.07e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—pancreatic cancer	2.75e-07	3.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—pancreatic cancer	2.73e-07	3.03e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—pancreatic cancer	2.72e-07	3.02e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—pancreatic cancer	2.72e-07	3.01e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—pancreatic cancer	2.71e-07	3e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—pancreatic cancer	2.71e-07	3e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	2.71e-07	3e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—pancreatic cancer	2.71e-07	3e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—pancreatic cancer	2.7e-07	2.99e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—pancreatic cancer	2.7e-07	2.99e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—pancreatic cancer	2.7e-07	2.99e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—pancreatic cancer	2.7e-07	2.99e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—pancreatic cancer	2.7e-07	2.99e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—pancreatic cancer	2.69e-07	2.98e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—pancreatic cancer	2.69e-07	2.98e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—pancreatic cancer	2.69e-07	2.98e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—pancreatic cancer	2.69e-07	2.98e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—pancreatic cancer	2.69e-07	2.98e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—pancreatic cancer	2.68e-07	2.97e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—pancreatic cancer	2.68e-07	2.97e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—pancreatic cancer	2.68e-07	2.96e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—pancreatic cancer	2.68e-07	2.96e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—pancreatic cancer	2.67e-07	2.96e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—pancreatic cancer	2.67e-07	2.96e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—pancreatic cancer	2.67e-07	2.96e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—pancreatic cancer	2.64e-07	2.93e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	2.64e-07	2.92e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—pancreatic cancer	2.64e-07	2.92e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—pancreatic cancer	2.63e-07	2.91e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—pancreatic cancer	2.63e-07	2.91e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—pancreatic cancer	2.62e-07	2.91e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—pancreatic cancer	2.62e-07	2.9e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—SRC—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	2.61e-07	2.89e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—pancreatic cancer	2.6e-07	2.88e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—SRC—pancreatic cancer	2.6e-07	2.88e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	2.58e-07	2.86e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—pancreatic cancer	2.57e-07	2.84e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—pancreatic cancer	2.55e-07	2.82e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—pancreatic cancer	2.54e-07	2.82e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—pancreatic cancer	2.53e-07	2.8e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—pancreatic cancer	2.52e-07	2.79e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—pancreatic cancer	2.51e-07	2.78e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—pancreatic cancer	2.51e-07	2.78e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—pancreatic cancer	2.5e-07	2.77e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—pancreatic cancer	2.5e-07	2.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—pancreatic cancer	2.5e-07	2.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—pancreatic cancer	2.5e-07	2.77e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—pancreatic cancer	2.5e-07	2.76e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—pancreatic cancer	2.49e-07	2.76e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—pancreatic cancer	2.49e-07	2.76e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—pancreatic cancer	2.49e-07	2.76e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—pancreatic cancer	2.49e-07	2.76e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—pancreatic cancer	2.48e-07	2.75e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SRC—pancreatic cancer	2.48e-07	2.75e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—pancreatic cancer	2.48e-07	2.75e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—pancreatic cancer	2.46e-07	2.73e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—pancreatic cancer	2.46e-07	2.73e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOE—pancreatic cancer	2.46e-07	2.72e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—pancreatic cancer	2.43e-07	2.7e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	2.43e-07	2.69e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	2.42e-07	2.68e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—pancreatic cancer	2.42e-07	2.68e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—pancreatic cancer	2.42e-07	2.68e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—pancreatic cancer	2.42e-07	2.68e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—pancreatic cancer	2.41e-07	2.67e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—pancreatic cancer	2.4e-07	2.66e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CD44—pancreatic cancer	2.4e-07	2.66e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—pancreatic cancer	2.39e-07	2.65e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—pancreatic cancer	2.39e-07	2.64e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—pancreatic cancer	2.39e-07	2.64e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—pancreatic cancer	2.38e-07	2.64e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	2.37e-07	2.63e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—pancreatic cancer	2.37e-07	2.63e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—pancreatic cancer	2.34e-07	2.59e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—pancreatic cancer	2.34e-07	2.59e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—pancreatic cancer	2.34e-07	2.59e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—pancreatic cancer	2.33e-07	2.59e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—pancreatic cancer	2.33e-07	2.58e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—pancreatic cancer	2.32e-07	2.57e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—pancreatic cancer	2.32e-07	2.57e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—pancreatic cancer	2.31e-07	2.55e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—pancreatic cancer	2.31e-07	2.55e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GCG—pancreatic cancer	2.3e-07	2.55e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—pancreatic cancer	2.3e-07	2.55e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—pancreatic cancer	2.29e-07	2.54e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—pancreatic cancer	2.29e-07	2.54e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—pancreatic cancer	2.29e-07	2.53e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—pancreatic cancer	2.28e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—pancreatic cancer	2.28e-07	2.52e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	2.25e-07	2.49e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	2.24e-07	2.48e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—pancreatic cancer	2.24e-07	2.48e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—pancreatic cancer	2.24e-07	2.48e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	2.23e-07	2.47e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—pancreatic cancer	2.22e-07	2.46e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—pancreatic cancer	2.22e-07	2.46e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—pancreatic cancer	2.22e-07	2.46e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	2.22e-07	2.46e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—pancreatic cancer	2.21e-07	2.45e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—pancreatic cancer	2.21e-07	2.45e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—pancreatic cancer	2.2e-07	2.44e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—pancreatic cancer	2.18e-07	2.41e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—STK11—pancreatic cancer	2.16e-07	2.4e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—pancreatic cancer	2.16e-07	2.39e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—pancreatic cancer	2.15e-07	2.38e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—pancreatic cancer	2.14e-07	2.37e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—pancreatic cancer	2.12e-07	2.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—pancreatic cancer	2.12e-07	2.34e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—pancreatic cancer	2.11e-07	2.34e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—pancreatic cancer	2.1e-07	2.32e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	2.06e-07	2.28e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—pancreatic cancer	2.06e-07	2.28e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—pancreatic cancer	2.04e-07	2.26e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—pancreatic cancer	2.04e-07	2.25e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—pancreatic cancer	2.01e-07	2.23e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	1.99e-07	2.21e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—pancreatic cancer	1.99e-07	2.2e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—pancreatic cancer	1.98e-07	2.19e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—pancreatic cancer	1.97e-07	2.19e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—pancreatic cancer	1.97e-07	2.19e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—pancreatic cancer	1.95e-07	2.16e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.95e-07	2.16e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.95e-07	2.16e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—pancreatic cancer	1.92e-07	2.13e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	1.92e-07	2.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—pancreatic cancer	1.91e-07	2.12e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	1.91e-07	2.11e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	1.9e-07	2.1e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—pancreatic cancer	1.89e-07	2.09e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—pancreatic cancer	1.87e-07	2.08e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—pancreatic cancer	1.87e-07	2.07e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.86e-07	2.06e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—pancreatic cancer	1.84e-07	2.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—pancreatic cancer	1.83e-07	2.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—pancreatic cancer	1.83e-07	2.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—pancreatic cancer	1.75e-07	1.94e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—pancreatic cancer	1.73e-07	1.91e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.7e-07	1.88e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.68e-07	1.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	1.68e-07	1.86e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—pancreatic cancer	1.62e-07	1.8e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—pancreatic cancer	1.61e-07	1.79e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—pancreatic cancer	1.57e-07	1.73e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.55e-07	1.72e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—pancreatic cancer	1.54e-07	1.71e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOE—pancreatic cancer	1.51e-07	1.68e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—pancreatic cancer	1.47e-07	1.63e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.37e-07	1.52e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.37e-07	1.51e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.32e-07	1.46e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.2e-07	1.33e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.12e-07	1.24e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.05e-07	1.16e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.04e-07	1.15e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.04e-07	1.15e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	9.05e-08	1e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—pancreatic cancer	8.46e-08	9.37e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	6.38e-08	7.07e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	5.21e-08	5.78e-07	CbGpPWpGaD
